Nonpeptide endothelin receptor antagonists attenuate the pressor effect of diaspirin-crosslinked hemoglobin in rat

Canadian Journal of Physiology and Pharmacology

Volumn 77, Issue 3, 1999, Pages 188-194

  Rioux, Francis ^a,c   Harvey, Nathalie ^a   Moisan, Steve ^a   Larivière, Richard ^a   Lebel, Marcel ^a   Grose, John H ^a   Burhop, Kenneth ^b  

^a LAVAL UNIVERSITY   (Canada)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Blood pressure; Diaspirin crosslinked hemoglobin (DCLHb); Endothelin; Hemoglobin; Nitric oxide

Indexed keywords

BOSENTAN; DARUSENTAN; DIASPIRIN CROSSLINKED HEMOGLOBIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HEART RATE; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT;

EID: 0032775689     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y99-019     Document Type: Article

References (30)

1. Banting, J.D., Friberg, P., and Adams, M.A. 1996. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J. Hypertens. 14: 975-981.
2. Boulanger, C., and Luscher, T.F. 1990. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 85: 587-590.
3. 2). J. Biol. Chem. 261: 9929-9937.
4. B receptor antagonist RO 46-8443. FEBS Lett. 383: 42-45.
5. Clozel, M., Breu, V., Gray, G.A., Kalina, B., Löffler, B.-M., Burri, K., Casal, J.-M., Harth, G., Müller, M., Nudhart, W., and Ramuz, H. 1994. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270: 228-235.
6. Deby-Dupont, G., Pincemail, J., and Lamy, M. 1994. Hemoglobin-based red cell substitute: preliminary human studies. Yearbook Intensive Emerg. Care Med., Springer-Verlag, New York. pp. 264-275.
7. Fink, J., Fan, N.Y.-T., Rosenfeld, L., and Stier, C.T., Jr. 1998. Contribution of endothelin to the acute pressor response of L-NAME in stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 31: 618-622.
8. Gulati, A., Sharma, A.C., and Singh, G. 1994. Regional circulatory effects of diaspirin crosslinked hemoglobin can be blocked by the endothelin (ET) antagonist, BQ-123. FASEB J. 8: A625 (Abstr. 3624).
9. Gulati, A., Singh, G., Rebello, S., and Sharma, A.C. 1995a. Effect of diaspirin crosslinked and stroma-reduced hemoglobin on mean arterial pressure and endothelin-1 concentration in rats. Life Sci. 56: 1433-1442.
10. Gulati, A., Singh, G., Sang, M.O., and Sen, A.P. 1995b. Role of endothelin-converting enzyme in the systemic hemodynamics and regional circulatory effects of proendothelin-1 (1-38) and diaspirin cross-linked hemoglobin in rats. J. Lab. Clin. Med. 126: 560-570.
11. Hamilton, I., Schultz, S.C., Cole, F., Burhop, K., and Malcom, D. 1992. Characterization of diaspirin crosslinked hemoglobin's pressor response. Crit. Care Med. 20: S106.
12. Harrison, V.J., Randriantsoa, A., and Schoeffter, P. 1992. Heterogeneity of endothelin-sarafotoxin mediating contraction of pig coronary artery. Br. J. Pharmacol. 105: 511-513.
13. King, A.J. 1995. Endothelins: multifunctional peptides with potent vasoactive properties. In Hypertension: pathophysiology, diagnosis and management. 2nd ed. Edited by J.H. Laragh and B.M. Brenner. Raven Press Ltd., New York. pp. 631-672.
14. Larivière, R., D'Amours, M., Lebel, M., Kingma, I., Grose, J.H., and Caron, L. 1997. Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Press. Res. 20: 372-380.
15. Levine, E.R. 1995. Endothelins. N. Engl. J. Med. 333: 356-363.
16. Luscher, T.F., Yang, Z., Tschudi, M., von Segesser, L., Stutz, P., Boulanger, C., Siebenmann, R., Turina, M., and Bühler, F.R. 1990. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ. Res. 66: 1088-1094.
17. Malcolm, D.S., Hamilton, I.N., Jr., Schultz, S.C., Cole, F., and Burhop, K. 1994. Characterization of the hemodynamic response to intravenous diaspirin crosslinked hemoglobin solution in rats. Artif. Cells Blood Substitutes Immobilization Biotechnol. 22: 91-107.
18. Martin, W., Villani, G.M., Jothianandan, D., and Furchgott, R.F. 1985. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J. Pharmacol. Exp. Ther. 232: 708-716.
19. Moisan, S., Drapeau, G., Burhop, K.E., and Rioux, F. 1998. Mechanism of the acute pressor effect and bradycardia elicited by diaspirin crosslinked hemoglobin in anesthetized rats. Can. J. Physiol. Pharmacol. 76: 434-442.
20. Moncada, M., Palmer, R.J., and Higgs, E.A. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43: 109-163.
21. Muldoon, S.M., Ledvina, M.A., Hart, J.L., and McDonald, W.W. 1996. Hemoglobin-induced contraction of pig pulmonary veins. J. Lab. Clin. Med. 128: 579-584.
22. A-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm. Pharmacol. Lett. 6: 90-92.
23. Nelson, D., Azari, M., Brown, R., Burhop, K., Bush, S., Catarello, F., Chuang, H., Downing, C., Estep, T., Loewen, A., McClure, K., McDaniel, A., Michalek, E., Mozier, N., Rohn, K., Spicuzza, J., Zieske, P., and Zimmerman, G. 1992. Preparation and characterization of diaspirin cross-linked hemoglobin solutions for preclinical studies. Biomater. Artif. Cells Immob. Biotech. 20: 423-427.
24. Przybelski, R.J., Dailey, E.K., Kisicki, J.C., Matthia-Goldberg, C., Bounds, M.J., and Colburn, W.A. 1996. Phase I study of the safety and pharmacologic effects of diaspirin crosslinked hemoglobin solution. Crit. Care Med. 24: 1993-2000.
25. Richard, V., Hogie, M., Clozel, M., Löffler, B.-M., and Thuillez, C. 1995. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation, 91: 771-775.
26. Rioux, F., Petitclerc, E., Audet, R., Drapeau, G., Fielding, R., and Marceau, F. 1994. Recombinant human hemoglobin inhibits both constitutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings. J. Cardiovasc. Pharmacol. 24: 229-237.
27. Schultz, S.C., Grady, B., Cole, F., Hamilton, I., Burhop, K., and Malcolm, D.S. 1993. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J. Lab. Clin. Med. 122: 301-308.
28. Snyder, S.R, Welty, E.V., Roxanne, R.Y., Williams, L.A., and Walder, J.A. 1987. HbXL99α: a hemoglobin derivative that is crosslinked between the α subunits is useful as a blood substitute. Proc. Natl. Acad. Sci. U.S.A. 84: 7280-7284.
29. B receptors mediate vascular smooth muscle cell contraction. Br. J. Pharmacol. 107: 858-860.
30. Yu, Z., Friso, G., Miranda, J.J., Patel, M.J., Lo-Tseng, T., Moore, E.G., and Burlingame, A.L. 1997. Structural characterization of human hemoglobin crosslinked by bis(3,5-dibromosalicyl)fumarate using mass spectrometric techniques. Protein Sci. 6: 2568-2577.